Phase 1 Study of C.001 in Retinal Degeneration
NCT07594236
Age Related Macular Degeneration, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Beverly Hills, California, United States
View Trial DetailsNCT Number: NCT07653269
The purpose of this research study is to evaluate a new screening procedure for the early detection and monitoring of Age-related Macular Degeneration (AMD) in community settings and community hospital settings, to identify associated risk factors, and develop personalized monitoring strategies for at-risk individuals throughout the 5 years follow up period, which will allow us to establish prevalence, natural history of progression of early AMD in the community.
Interested in participating?
Request Info55 year and older
All sexes
Observational
Outram Community Hospital, Singapore
An effective screening programme requires several key components to be successful. First, the natural history of the condition needs to be well understood. Next, a clear threshold for referral must be established and finally, effective intervention must be available to treat the condition in question. In ophthalmology, the most effective screening programme we have is for diabetic retinopathy (DR). Here, the natural history and thresholds are well established, and treatment in the form of pan-retinal photocoagulation is effective in preventing progression to visually threatening DR.
While there is consensus regarding features that predispose to late AMD, at an individual level, risk, rate and pattern of progression remain unpredictable therefore there is a need to develop effective AMD screening. This is in contrast to diabetic retinopathy because the natural history is well understood and the risk of vision loss increases sharply in those with referrable DR. In AMD, this threshold is not yet established.
As there is currently no standardized screening protocol for early AMD, especially in the community-based setting and community hospital settings, our study aims to understand the natural progression of AMD in the elderly and establish a referrable threshold before visually threatening AMD occurs. This will ultimately inform a comprehensive and standardized community-based screening approach for AMD.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 years
Progression is defined as the change from early signs of AMD to advanced AMD.
Contact information is provided by the study sponsor or research team.
Singapore National Eye Centre
Other Gov
Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation - PRIME Study
Acronym: PRIME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07594236
Age Related Macular Degeneration, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Beverly Hills, California, United States
View Trial DetailsNCT06943599
Age Related Macular Degeneration, Behavior
San Francisco, California, United States
View Trial DetailsNCT07461441
Age Related Macular Degeneration, Choroid Diseases
Daegu, Namgu, South Korea
View Trial DetailsNCT07235527
Age Related Macular Degeneration, Anti Vascular Endothelial Growth Factor
Istanbul, şişli, Turkey (Türkiye)
View Trial Details